Claims
- 1. An anti-atherosclerotic synthetic peptide, said peptide being an amphipathic helical peptide compared with human apoA-I, characterized by having at least 4 of the following 8 properties: a tandem repeating class A amphipathic helix linked by a proline which forms an optimal arrangement for lipid association, has lipid bilayer membrane stabilizing properties, inhibits HIV-I GP41-induced cell fusion, inhibits neutrophil activation, inhibits bovine serum albumin-induced lysis of fatty acid-containing vesicles, stimulates human placental lactogen synthesis, effluxes phospholipid and cellular cholesterol from cholesterol-laced cells, and competes with HDL for binding to cells; wherein said peptide has the sequence shown in SEQ ID NO. 3.
- 2. A pharmaceutical composition, comprising a peptide of claim 1 and a pharmaceutically acceptable carrier.
- 3. A method of treating atherosclerosis in an animal in need of such treatment, comprising the step of:
- administering to the animal a pharmacologically effective dose of the pharmaceutical composition of claim 2.
- 4. A class A amphipathic helical peptide, said peptide synthesized as a head-to-tail dimer with a proline incorporated therein, wherein said peptide mimicks the properties of human apoA-I, and wherein said peptide has the sequence shown in SEQ ID NO. 3.
Parent Case Info
This application claims the benefit of U.S. Provisional application Ser. No. 60/025,505, filed Sep. 5, 1996 (MPEP .sctn.1302.04).
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4643988 |
Segrest et al. |
Feb 1987 |
|
Non-Patent Literature Citations (1)
Entry |
Tytler et al. Synthetic peptides in the study of viral fusion, inflammation, and athersclerosis. In: Peptides: design, synthesis, and biological activity. Basava and Anantharamaiah, editors, p. 113-132, 1994. |